Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Zacharon Pharmaceuticals Announces R & D Collaboration With Pfizer

By Pharmaceutical Processing | April 7, 2011

Zacharon Pharmaceuticals, Inc. today announced that the
company has entered into a strategic research collaboration with Pfizer Inc. to
develop drugs for orphan diseases, including lysosomal storage disorders. The potential
value of the collaboration to Zacharon is approximately USD $210 million.

The collaboration includes the potential development of
compounds that may be discovered using Zacharon’s innovative platform for
developing small molecule drugs targeting specific carbohydrate polymers or glycans.

Zacharon, whose sole venture investor is Avalon Ventures,
will receive up-front payments and research and development funding under the collaboration
to develop drugs against targets that impact lysosomal storage diseases.
Zacharon is also eligible under the collaboration for payments for meeting
development milestones, plus royalties and sales milestones upon
commercialization.

“We are very pleased to be working with Pfizer, which
has broad compound development expertise, including in the area of small molecules,
which should be quite useful to developing drugs for these orphan
diseases,” said Robin Jackman, Ph.D., president and CEO of Zacharon.
“The collaboration provides validation for the potential that lies in
Zacharon’s broadly applicable technology platform.” Ed Mascioli, M.D.,
head of Pfizer’s Orphan & Genetic Diseases Unit, said: “Part of
Pfizer’s Orphan & Genetic Diseases Unit’s strategic focus relies on
collaborations with companies like Zacharon that have promising technologies to
help develop treatments for rare diseases.

Zacharon is an ideal partner, and we look forward to working
with them to develop treatments for lysosomal storage diseases.”  

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards